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Abstract
Background—Annual influenza vaccination is recommended for all persons ≥6 months. The 
objective of this study is to assess trends in racial/ethnic disparities in influenza vaccination 
coverage among adults in the United States.
Methods—We analyzed data from the 2007-2012 National Health Interview Survey (NHIS) and 
Behavioral Risk Factor Surveillance System (BRFSS) using the Kaplan-Meier survival analysis 
procedure to assess influenza vaccination coverage by age, presence of medical conditions, and 
racial/ethnic groups during the 2007-08 through 2011-12 seasons.
Results—During the 2011-12 season, influenza vaccination coverage was significantly lower 
among non-Hispanic blacks and Hispanics compared with non-Hispanic whites among most of the 
adult sub-groups, with smaller disparities observed for adults 18-49 years compared to other age 
groups. Vaccination coverage for non-Hispanic white, non-Hispanic black, and Hispanic adults 
increased significantly from the 2007-08 through the 2011-12 season for most of the adult sub-
groups based on NHIS (test for trend: p<0.05). Coverage gaps between racial/ethnic minorities 
and non-Hispanic white persisted at similar levels from the 2007-08 through the 2011-12 season, 
with similar results from NHIS and BRFSS.
Conclusions—Influenza vaccination coverage among most racial/ethnic groups increased from 
the 2007-08 through the 2011-12 seasons, but substantial racial and ethnic disparities remained in 
most age groups. Targeted efforts are needed to improve coverage and reduce disparities.
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Introduction
Annual influenza epidemics typically occur during the late fall through early spring in the 
United States. Influenza is a major cause of morbidity and mortality among adults in the 
United States (1-6). Between the 1976–77 season and 2006–07 season, estimated annual 
deaths attributable to influenza ranged from 3,000 to 49,000 each season (2). The economic 
impact of influenza illness is substantial. One national study estimated the annual economic 
burden of seasonal influenza in the United States to be $87.1 billion, including $10.4 billion 
in direct medical costs (7).
Since the 2010-11 influenza season, the Advisory Committee on Immunization Practices 
(ACIP) has recommended annual influenza vaccination for all persons 6 months of age and 
older. Prior to 2010, adult groups recommended for annual vaccination included persons 50 
years and older, pregnant women, persons 18-49 years with medical conditions associated 
with higher risk of complications from influenza infection, health care personnel, and close 
contacts of high risk persons (8). Healthy adults 18-49 years who were not close contacts of 
persons at high risk were added to those recommended for annual vaccination beginning in 
the 2010-11 season (3).
Mortality and morbidity associated with influenza are substantial, particularly among the 
elderly and those with chronic conditions who are most at risk for secondary infections. 
Annual vaccination is the most effective strategy for preventing influenza (3, 5-23). 
Vaccination coverage has been suboptimal, and racial/ ethnic disparities in influenza 
vaccination coverage have been documented (3, 24-31). To assess the level and trend of 
racial and ethnic disparities in influenza vaccination of adults, we analyzed 2007-2012 
National Health Interview Survey (NHIS) and Behavioral Risk Factor Surveillance System 
(BRFSS) data.
Methods
The BRFSS and NHIS are two primary data sources used to monitor influenza vaccination 
coverage among adults (25-32), with NHIS providing national estimates used to monitor 
progress toward national Healthy People 2020 objectives (33), and BRFSS for more timely 
national and state-specific estimates (34). BRFSS has larger sample size and thus provides a 
more detailed examination of racial/ethnic groups. These surveys differ in their sampling 
design, mode of administration, response rates and other methodological aspects. We 
examine racial/ethnic disparities using both data sources and provide a synthesis of evidence 
on disparities using both data sources.
We estimated influenza vaccination coverage among adults using 2007-2012 NHIS data and 
2007-2012 BRFSS data. We did not use the annual BRFSS public release data, but monthly 
or quarterly weighted files created by CDC for more timely estimates of season-specific 
influenza vaccination coverage. The NHIS is a national cross-sectional household survey 
conducted annually by the Centers for Disease Control and Prevention (CDC) to provide 
estimates of health indicators, health care utilization and access, and health-related behaviors 
(30, 35). The survey samples civilian, non-institutionalized populations living in the United 
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States at the time of the survey. Multistage probability samples of households are selected 
weekly throughout the year, and face-to-face interviews are conducted. Weights are based on 
design, ratio, non-response, and post-stratification adjustments (sex, age, race/ethnicity). The 
BRFSS is a continuous, population-based telephone survey conducted by state health 
departments in collaboration with the CDC to collect uniform, state-specific data on self-
reported preventive health practices and risk behaviors that are linked to preventable 
infectious diseases, chronic diseases, and injuries. Non-institutionalized adults ≥18 years are 
randomly selected using a multistage cluster design. Data are collected monthly in all 50 
states and D.C. and are weighted by age, sex, and, in some states, race/ethnicity, to reflect 
each area’s estimated adult population (36). Beginning in 2011, surveys included landline 
and cellular telephone households and used a new method for weighting (37).
For NHIS survey, respondents were asked “During the past 12 months, have you had a flu 
shot?” and “During what month and year did you receive your most recent seasonal flu 
shot?” “The seasonal flu vaccine sprayed in the nose is also called FluMist™. During the 
past 12 months, have you had a seasonal flu vaccine that was sprayed in your nose?” and 
“During what month and year did you receive your most recent seasonal flu vaccine that was 
sprayed in your nose?” For BRFSS, prior to 2011, influenza vaccination questions were 
worded similarly as for NHIS; starting from 2011, BRFSS respondents were asked “During 
the past 12 months, have you had either a seasonal flu shot or a seasonal flu vaccine that was 
sprayed in your nose?” and “During what month and year did you receive your most recent 
flu shot injected into your arm or flu vaccine that was sprayed in your nose?”
Compared to BRFSS, the NHIS collects more information regarding high-risk conditions to 
enable categorization of adults who had health conditions that put them at high risk for 
complications from influenza (34). For respondents included in the NHIS samples, we 
defined high-risk persons as individuals who self-reported one or more of the following: ever 
being told by a physician they had diabetes, emphysema, coronary heart disease, angina, 
heart attack or other heart condition; being diagnosed with cancer in the past 12 months 
(excluding non-melanoma skin cancer) or ever being told by a physician they have 
lymphoma, leukemia or blood cancer; during the past 12 months, being told by a physician 
they have chronic bronchitis or weak or failing kidneys; or reporting an asthma episode or 
attack in the past 12 months. For respondents included in the BRFSS samples, we defined 
high-risk persons as individuals who self-reported they had diabetes, asthma, myocardial 
infarction, and coronary heart disease, the relevant medical conditions collected by BRFSS.
We assessed influenza vaccination among adult populations and stratified by race/ethnicity. 
To better assess influenza vaccination coverage for each season, we reported coverage 
restricted to individuals interviewed during September through June, and vaccinated during 
August through May, using the Kaplan-Meier survival analysis procedure (34). For example, 
for the 2010-11 season, interviews during September 2010 through June 2011 were analyzed 
to estimate influenza vaccination received during August 2010 through May 2011. For the 
2007-08 season, 2008 BRFSS interviews from January-June 2008 were used since month 
and year of vaccination was first added to BRFSS in the 2008 BRFSS data. For the 2009-10 
season, interviews from October 2009 through June 2010 were used. Vaccination month was 
used to define the “event” variable and interview date to define the “censoring” variable of 
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the Kaplan Meier procedure. Tests for linear trend were performed using a weighted linear 
regression on the season-specific estimates using season number as the independent variable 
and weights as the inverse of the estimated variance of the estimated vaccination coverage. 
Racial/ethnic differences within each group were assessed with t-tests. All analyses were 
weighted to reflect the age, sex, and race/ethnicity of the U.S. non-institutionalized, civilian 
population. Vaccination month and year were imputed for individuals who did not report 
their month and year of vaccination (range by season was 3.0-5.0% for NHIS and 3.5-7.3% 
for BRFSS). All tests were 2-tailed with the significance level set at α<0.05. SAS and 
SUDAAN (Software for the statistical analysis of correlated data, Research Triangle 
Institute, Research Triangle Park, NC, version 10.01) were used to calculate point estimates 
and 95% confidence intervals (CIs).
Results
Overall, among adults ≥18 years, influenza vaccination coverage in the 2011-12 season 
based on NHIS was 42.4% for non-Hispanic whites, 34.0% for non-Hispanic blacks, 28.3% 
for Hispanics, 42.3% for American Indian and Alaska Natives (AIAN), 42.0% for Asians, 
and 34.2% for other or multiple races; based on BRFSS, coverage was 41.9% for non-
Hispanic whites, 32.7% for non-Hispanic blacks, 29.4% for Hispanics, 37.3% for AIAN, 
42.6% for Asians, and 33.9% for other or multiple races (Table 1).
During the 2011-12 season, overall among adults ≥18 years, the gap in influenza vaccination 
coverage between racial/ethnic minorities and non-Hispanic whites (minorities minus non-
Hispanic whites) ranged from −14.1 to −0.1 percentage points based on NHIS, and −12.5 to 
0.7 percentage points based on BRFSS (Table 2).
During the 2011-12 season, vaccination coverage was significantly lower among non-
Hispanic blacks and Hispanics compared with non-Hispanic whites as measured by NHIS 
and BRFSS for most age groups (NHIS: ≥18 years, 18–64 years, 18-64 years without high-
risk conditions, 50-64 years, and ≥65 years for non-Hispanic blacks, all age groups for 
Hispanics (Table 1-2, Figure 1); BRFSS: all age groups for non-Hispanic blacks, all age 
groups for Hispanics except for ≥65 years) (Table 1-2). Vaccination coverage was similar for 
AIAN, Asians, and other or multiple races compared with non-Hispanic whites as measured 
by NHIS and BRFSS for most age groups (NHIS: all age groups for AIAN, all age groups 
except for 18-49 years, and 18-64 years without high-risk conditions for Asians, all age 
groups except for ≥18 years for other or multiple race; BRFSS: all age groups except for 
18-49 years and ≥18 years for AIAN, all age groups except for 18-49 years for Asians, all 
age groups except for ≥18 years, 18-64 years, and 18-64 years without high-risk conditions 
for other or multiple race) (Table 1-2).
Overall, among adults ≥18 years, during the 2011-12 season, the BRFSS estimate was 
similar to the NHIS estimate, with a percentage point difference of (BRFSS minus NHIS) 
−0.4%. Percentage point differences between BRFSS and NHIS estimates among all adults 
≥18 years by racial/ethnic groups ranged from −5.0% to 1.1%. Percentage point differences 
between BRFSS and NHIS among other adult age groups by racial/ethnic groups ranged 
from −14.5% to 8.8% (Table 1). Among age and high-risk groups, percentage point 
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differences between BRFSS and NHIS estimates were statistically significant for adults aged 
18-49 years (percentage point difference: 1.5%, p<0.05), and ≥65 years (percentage point 
difference: −5.2%%, p<0.05) (Table 1). Among racial/ethnic groups, percentage point 
differences between BRFSS and NHIS estimates were statistically significant for non-
Hispanic white adults aged 18-49 years (percentage point difference: 2.0%, %, p<0.05), 
50-64 years (percentage point difference: −2.4%%, p<0.05), and ≥65 years (percentage point 
difference: −6.1%%, p<0.05) (Table 1). Percentage point differences between BRFSS and 
NHIS estimates were not statistically significant for non-Hispanic blacks, Hispanics, AIAN, 
Asians, and other or multiple races (Table 1).
As measured by NHIS, vaccination coverage for non-Hispanic white, non-Hispanic blacks, 
and Hispanic adults significantly increased by a per season average of 1-2 percentage points 
from the 2007-08 through the 2011-12 seasons for most age groups aged <65 years (test for 
trend: p<0.05) (all age groups except for ≥65 years and 18-64 years with high-risk 
conditions for non-Hispanic whites; ≥18 years, 18-64 years, 18-49 years, and 18-64 years 
without high-risk conditions for non-Hispanic blacks; ≥18 years, 18-64 years, 18-49 years, 
and 18-64 years without high-risk conditions for Hispanics) (Table 3, Figure 1). Vaccination 
coverage for Asian adults significantly increased by a per season average of about 3 
percentage points increases from the 2007-08 through the 2011-12 seasons for adults aged 
18-49 years, and 18-64 years without high-risk conditions (test for trend: p<0.05) (Table 3). 
As measured by BRFSS, test for trends by race/ethnicity were not statistically significant 
except for a 2.5% average per season decrease among non-Hispanic white adults aged ≥65 
years and 1.3% average season increase among Asians aged 18-64 years without high-risk 
conditions (Table 3).
During the 2007-08 through the 2011-12 seasons, coverage gaps between racial/ethnic 
minorities and non-Hispanic whites did not significantly change as measured by NHIS and 
BRFSS for most age groups (test for trend: p>0.05) (NHIS: all age groups for non-Hispanic 
blacks, Hispanics, and other or multiple races, all age groups for Asians except for 18-49 
years; BRFSS: test for trends by gaps between racial/ethnic minorities and non-Hispanic 
white were not significant except for those 50-64 years for Hispanics) (Table 4).
Discussion
Our findings showed that, by the 2011-12 season, racial/ethnic disparities in influenza 
vaccination among adult populations remained although vaccination coverage among non-
Hispanic white, non-Hispanic black, and Hispanics significantly increased during the 
2007-08 season through 2011-12 season for most age groups. Among most adult sub-groups 
examined, smaller disparities in the 18-49 year age group were observed compared to other 
age groups. Compared with non-Hispanic whites, vaccination coverage is particularly lower 
among non-Hispanic blacks and Hispanics. Coverage for the 2011-12 season was higher 
compared to non-Hispanic whites for several racial/ethnic and age subgroups (Asians 18-49 
years based on NHIS and BRFSS, Asians 18-64 years without high risk conditions from 
NHIS, and American Indian and Alaskan Natives 18-49 years from BRFSS). Among each 
racial/ethnic group, vaccination coverage varied by age group and high-risk conditions status 
in a consistent manner.
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Overall, coverage among all racial/ethnic groups remains suboptimal. By the 2011-12 
season, influenza vaccination coverage among all adults ≥18 years by racial/ethnic groups 
was 28-42% based on NHIS, and 29-43% based on BRFSS, which were substantially below 
Healthy People 2020 goals of 70% for adults aged ≥18 years (33). The universal vaccination 
recommendation eliminates the need to determine whether each person has one or more 
specific indications for vaccination and emphasizes the importance of preventing influenza 
among persons of all ages (3). Monitoring of annual influenza vaccination coverage among 
adults ≥18 years by race/ethnicity is important to assess the impact of the vaccination 
program and to focus efforts on groups with lagging coverage.
Previous research shows significant racial/ethnic disparities in influenza vaccination 
coverage among adults (25, 27-30, 38). We found that vaccination coverage among most 
adult sub-groups that were analyzed was significantly higher among non-Hispanic whites 
compared with non-Hispanic blacks and Hispanics. Gaps in coverage are long-standing and 
likely result from a combination of factors, including differences in: socio-demographic 
characteristics, patients and provider attitudes toward vaccination, awareness of 
recommendations, systems used in clinics serving different patient populations, preventive 
care, propensity to seek and accept vaccination, and quality of care received by racial/ethnic 
populations (3, 28, 29, 39-43). Broad use of interventions to remove barriers to access and to 
make offering of vaccination in health care and other settings a routine practice are 
important components of efforts to reduce these disparities (43, 44). Efforts to reduce 
disparities may be most important for older adults given smaller disparities in adults 18-49 
years.
The CDC publishes influenza vaccination coverage estimates among adults from several 
data sources, including NHIS and BRFSS (32, 34). For adults, BRFSS estimates provide 
timely national and state-specific estimates that are available by the time the next influenza 
vaccination campaigns begin. The National Health Interview Survey (NHIS) provides 
national estimates used for monitoring Healthy People 2020 objectives (33) but is less timely 
than BRFSS. The NHIS is a national household survey conducted mostly by face-to-face 
interviews with higher response rates (60-70%) than the BRFSS, a telephone survey with 
lower response rates (50-60%) (35, 36). The NHIS provides a more complete set of high-risk 
conditions and has provided season-specific estimates using self-reported month and year of 
most recent influenza vaccination since 2005, while BRFSS has provided these estimates 
since 2008.
There were few statistically significant differences in estimated influenza vaccination 
coverage between NHIS and BRFSS among the racial/ethnic, age and risk groups examined, 
although 95% confidence intervals for differences were wide for some racial/ethnic and age/
risk combinations, particularly for AIAN, Asians and Multiple race/others. However, a very 
similar level and pattern of differences in influenza vaccination coverage between racial/
ethnic groups compared to non-Hispanic whites was observed based on both BRFSS and 
NHIS. The NHIS provides a means to assess the potential validity of estimates from more 
timely data sources. BRFSS estimates among age groups often followed the NHIS pattern, 
except for adults ≥ 65 years in recent seasons, where BRFSS estimates were lower. While 
NHIS estimates for adults ≥65 years appear stable in recent seasons aside from a dip during 
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2009-10, BRFSS estimates for this age group indicate a possible decline, with estimates of 
74% for 2008-09, 67% for 2010-11, and 65% for 2011-12 (32). However, both data sources 
indicate coverage in older adults is 65-70% with much room for improvement. Ongoing 
comparisons of NHIS and other sources of influenza vaccination coverage over several 
seasons are needed. These comparisons will provide a better assessment of the validity of 
signals in trends and disparities identified from other data sources. Factors that may 
contribute to the differences in estimated coverage between NHIS and other data sources 
include a more representative sample frame and higher response rates for NHIS, survey 
mode (in-person for NHIS, telephone or internet for others), and differences in survey 
operations and weighting procedures. Starting in 2008, BRFSS began sampling persons in 
households with only cellular telephone service in each state to the landline telephone 
sampling frame (34, 45). Beginning in 2011, BRFSS included both landline and cellular 
telephone households in final data sets. The 2011-12 estimates from BRFSS in this report 
were based on data from this dual frame design, and thus may affect coverage estimates (34, 
45).
Our study is subject to several limitations. First, influenza vaccination status and high-risk 
conditions were self-reported and were not validated with medical records. Second, for the 
2009-10 season when both seasonal vaccine and monovalent pH1N1 vaccines were 
available, it is possible that some persons may have confused receipt of pH1N1 vaccination 
and seasonal influenza vaccination, with potential for over- or under-estimation of coverage 
for seasonal vaccine in 2009-10. Third, information was not available for some high-risk 
conditions in BRFSS identified by ACIP. Finally, our study is not further stratified or 
adjusted in multivariable analysis for the racial/ethnic disparities by socio-demographic 
variables.
Vaccination coverage in all groups recommended for vaccination remains suboptimal. 
Substantial improvement in annual influenza vaccination of recommended groups is needed 
to maximally reduce the health impact of influenza. It is important to continue to monitor 
vaccination coverage levels and racial/ethnic disparities over subsequent influenza seasons.
To improve coverage and eliminate disparities in adult influenza vaccination, evidence-based 
interventions are needed, including the use of reminder/recall systems, standing orders for 
vaccination, regular assessments of vaccination coverage levels among provider practices, 
vaccination registries, improving public and provider awareness of the importance of 
vaccinations for adults, public financing of recommended vaccines, and most importantly, 
identifying where vaccination coverage levels are low and using the information to target 
interventions (3, 46).
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Figure 1. Influenza Vaccination Coverage, U.S., Persons Aged ≥ 18 Years, by Race/Ethnicity
(Source: National Health Interview Survey, the 2007-08 to 2011-12 seasons)
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 c
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-re
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 m
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 b
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 b
y 
a 
ph
ys
ic
ia
n 
th
ey
 h
ad
 
di
ab
et
es
, e
m
ph
ys
em
a,
 c
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t d
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r d
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 c
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 c
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r d
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io
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 to
ld 
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th
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s o
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 d
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 d
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 c
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